Amphastar Pharmaceuticals (AMPH) Short term Debt (2013 - 2026)

Amphastar Pharmaceuticals' Short term Debt history runs 14 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Short term Debt rose 645.98% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 645.98% YoY), while the FY2025 annual figure was $1.6 million, up 601.28% from the prior year.
• Short term Debt was $1.7 million for Q1 2026 at Amphastar Pharmaceuticals, up from $1.6 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $12.9 million in Q2 2023 to a low of $224000.0 in Q1 2025.
• Historically, Short term Debt has averaged $1.8 million across 5 years, with a median of $927000.0 in 2025.
• The sharpest annual moves came in 2024 and 2026: Short term Debt tumbled 98.07% in 2024, then soared 645.98% in 2026.
• A 5-year view of Short term Debt shows it stood at $3.0 million in 2022, then sank by 85.69% to $436000.0 in 2023, then plunged by 46.33% to $234000.0 in 2024, then soared by 601.28% to $1.6 million in 2025, then advanced by 1.83% to $1.7 million in 2026.
• The last three Short term Debt figures came in at $1.7 million (Q1 2026), $1.6 million (Q4 2025), and $923000.0 (Q3 2025), per Business Quant data.